Stephanie K. Dougan, Ph.D.
Affiliations: | 2007 | Harvard University, Cambridge, MA, United States |
Google:
"Stephanie Dougan"Mean distance: 13.09
Parents
Sign in to add mentor| Richard S. Blumberg | grad student | 2007 | Harvard | |
| (The role of MTP in CD1d antigen presentation and NKT cell development.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Huang YH, Zhu C, Kondo Y, et al. (2024) Author Correction: CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature |
| Kureshi R, Bello E, Kureshi CTS, et al. (2023) DGKα/ζ inhibition lowers the TCR affinity threshold and potentiates antitumor immunity. Science Advances. 9: eadk1853 |
| Kurmi K, Liang D, van de Ven R, et al. (2023) Metabolic modulation of mitochondrial mass during CD4 T cell activation. Cell Chemical Biology |
| Ventre KS, Roehle K, Bello E, et al. (2023) cIAP1/2 Antagonism Induces Antigen-Specific T Cell-Dependent Immunity. Journal of Immunology (Baltimore, Md. : 1950) |
| Quijano-Rubio A, Bhuiyan AM, Yang H, et al. (2022) A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy. Nature Biotechnology |
| Stump CT, Roehle K, Manjarrez Orduno N, et al. (2021) Radiation combines with immune checkpoint blockade to enhance T cell priming in a murine model of poorly immunogenic pancreatic cancer. Open Biology. 11: 210245 |
| Roehle K, Qiang L, Ventre KS, et al. (2021) cIAP1/2 antagonism eliminates MHC class I-negative tumors through T cell-dependent reprogramming of mononuclear phagocytes. Science Translational Medicine. 13 |
| Heckler M, Ali LR, Clancy-Thompson E, et al. (2021) Inhibition of CDK4/6 promotes CD8 T-cell memory formation. Cancer Discovery |
| Luoma AM, Suo S, Williams HL, et al. (2020) Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. Cell |
| Crowley SJ, Bruck PT, Bhuiyan MA, et al. (2020) Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH. Open Biology. 10: 190235 |